Distinguished in Breast Cancer

Dr. Delphine W. Ong

Oncology
3301 C Street, Building 500, 
Sacramento, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Breast Cancer
3301 C Street, Building 500, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Delphine Ong is an Oncologist in Sacramento, California. Dr. Ong is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Classical Hodgkin Lymphoma.

Her clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

3301 C Street, Building 500, Sacramento, CA 95816

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Distinguished in Breast Cancer
Dr. Tiffany H. Svahn
Hematology Oncology | Hematology | Oncology
Distinguished in Breast Cancer
Dr. Tiffany H. Svahn
Hematology Oncology | Hematology | Oncology

John Muir Physician Network

2400 Balfour Rd, Suite 230, 
Brentwood, CA 
 (47.8 miles away)
925-671-0610
Languages Spoken:
English, French
See accepted insurances
Offers Telehealth

Tiffany Svahn is a Hematologist Oncology specialist and a Hematologist in Brentwood, California. Dr. Svahn is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Rajeswari Chellappah
Distinguished in Breast Cancer
Dr. Rajeswari Chellappah
Oncology
Distinguished in Breast Cancer
Dr. Rajeswari Chellappah
Oncology

8 Medical Plaza Care Center

8 Medical Plaza Drive, Suite 300, 
Roseville, CA 
 (17.0 miles away)
916-782-5106
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajeswari Chellappah is an Oncologist in Roseville, California. Dr. Chellappah is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Angiosarcoma, Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Chellappah is currently accepting new patients.

Distinguished in Breast Cancer
Dr. Ann M. Wexler
Oncology | Hematology Oncology
Distinguished in Breast Cancer
Dr. Ann M. Wexler
Oncology | Hematology Oncology
100 Hospital Drive, Suite 110, 
Vallejo, CA 
 (52.7 miles away)
707-551-3300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ann Wexler is a Hematologist Oncology specialist and an Oncologist in Vallejo, California. Dr. Wexler is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Colorectal Cancer. Dr. Wexler is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ong's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile